Cytokinetics Future Growth

Future criteria checks 2/6

Cytokinetics is forecast to grow earnings and revenue by 53.9% and 54.7% per annum respectively. EPS is expected to grow by 55.7% per annum. Return on equity is forecast to be -31.3% in 3 years.

Key information

53.9%

Earnings growth rate

55.7%

EPS growth rate

Biotechs earnings growth	21.2%
Revenue growth rate	54.7%
Future return on equity	-31.3%
Analyst coverage	Good
Last updated	15 Apr 2024

Recent future growth updates

Recent updates

Cytokinetics, Incorporated: Buyout Speculation Persists

Apr 01

Cytokinetics: CEO Talks Down Buyout Prospects

Mar 16

Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)

Jan 12

An Intrinsic Calculation For Cytokinetics, Incorporated (NASDAQ:CYTK) Suggests It's 37% Undervalued

Oct 05

Analysts Are Betting On Cytokinetics, Incorporated (NASDAQ:CYTK) With A Big Upgrade This Week

May 07

Analysts Are Betting On Cytokinetics, Incorporated (NASDAQ:CYTK) With A Big Upgrade This Week

Mar 03

Cytokinetics, Incorporated's (NASDAQ:CYTK) Intrinsic Value Is Potentially 100% Above Its Share Price

Jan 20

Newsflash: Cytokinetics, Incorporated (NASDAQ:CYTK) Analysts Have Been Trimming Their Revenue Forecasts

Dec 15

Cytokinetics: Surprise Adcomm For Omecamtiv Causing Concern

Oct 17

Cytokinetics gets monitoring panel's nod to continue phase 3 trial of ALS drug reldesemtiv

Oct 10

Cytokinetics (NASDAQ:CYTK) Has Debt But No Earnings; Should You Worry?

Aug 23

Earnings and Revenue Growth Forecasts

NasdaqGS:CYTK - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	512	-134	-236	-140	11
12/31/2025	165	-353	-390	-363	18
12/31/2024	12	-466	-451	-415	18
12/31/2023	8	-526	-416	-414	N/A
9/30/2023	8	-527	-443	-438	N/A
6/30/2023	10	-540	-437	-426	N/A
3/31/2023	98	-431	-406	-395	N/A
12/31/2022	95	-389	-311	-300	N/A
9/30/2022	148	-282	-272	-246	N/A
6/30/2022	151	-216	-236	-201	N/A
3/31/2022	65	-258	-183	-140	N/A
12/31/2021	70	-215	-191	-143	N/A
9/30/2021	22	-229	-83	-46	N/A
6/30/2021	58	-156	-17	8	N/A
3/31/2021	59	-135	-7	10	N/A
12/31/2020	56	-127	-2	9	N/A
9/30/2020	54	-114	-68	-62	N/A
6/30/2020	19	-140	-101	-97	N/A
3/31/2020	22	-132	-98	-94	N/A
12/31/2019	27	-122	-94	-91	N/A
9/30/2019	31	-118	-86	-84	N/A
6/30/2019	36	-110	-97	-96	N/A
3/31/2019	35	-105	-99	-98	N/A
12/31/2018	32	-106	-102	-101	N/A
9/30/2018	22	-120	-114	-113	N/A
6/30/2018	18	-131	-108	-106	N/A
3/31/2018	14	-132	-112	-111	N/A
12/31/2017	13	-128	-105	-102	N/A
9/30/2017	47	-80	N/A	0	N/A
6/30/2017	99	-14	N/A	14	N/A
3/31/2017	102	3	N/A	34	N/A
12/31/2016	106	16	N/A	37	N/A
9/30/2016	83	0	N/A	-51	N/A
6/30/2016	32	-42	N/A	-49	N/A
3/31/2016	33	-41	N/A	-47	N/A
12/31/2015	29	-38	N/A	5	N/A
9/30/2015	41	-20	N/A	7	N/A
6/30/2015	42	-17	N/A	8	N/A
3/31/2015	43	-15	N/A	7	N/A
12/31/2014	47	-15	N/A	-45	N/A
9/30/2014	50	-17	N/A	-49	N/A
6/30/2014	45	-23	N/A	-29	N/A
3/31/2014	38	-30	N/A	-13	N/A
12/31/2013	31	-34	N/A	-8	N/A
9/30/2013	8	-52	N/A	-2	N/A
6/30/2013	6	-49	N/A	-22	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CYTK is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CYTK is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CYTK is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CYTK's revenue (54.7% per year) is forecast to grow faster than the US market (8% per year).

High Growth Revenue: CYTK's revenue (54.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CYTK is forecast to be unprofitable in 3 years.

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Cytokinetics Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus revenue estimates decrease by 49%, EPS upgraded

Cytokinetics, Incorporated Provides Revenue Guidance for 2024

Price target increased by 20% to US$74.39

Consensus revenue estimates increase by 11%

Price target decreased to US$62.00

Consensus forecasts updated

Recent updates

Insider exercised options and sold US$1.9m worth of stock

Cytokinetics, Incorporated, Annual General Meeting, May 15, 2024

Cytokinetics Presents Additional 48-Week Data from Forest-Hcm, the Open Label Extension Clinical Study of Aficamten, At the American College of Cardiology 73rd Annual Scientific Session

Cytokinetics, Incorporated: Buyout Speculation Persists

Cytokinetics: CEO Talks Down Buyout Prospects

Insider notifies of intention to sell stock

Consensus revenue estimates decrease by 49%, EPS upgraded

Cytokinetics, Incorporated Provides Revenue Guidance for 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Cytokinetics, Incorporated to Report Q4, 2023 Results on Feb 27, 2024

Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw as Chief Financial Officer, Effective February 23, 2024

Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw as Chief Financial Officer, Effective February 23, 2024

Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw, Senior Vice President, Effective February 23, 2024

CEO, President & Director notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

Novartis Pursuit of Cytokinetics Reportedly Cools

Novartis Pursuit of Cytokinetics Reportedly Cools

Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)

Novartis Reportedly in Advanced Talks to Buy Cytokinetics

Novartis Reportedly in Advanced Talks to Buy Cytokinetics

CEO, President & Director notifies of intention to sell stock

Cytokinetics, Incorporated Announces Positive Results from Sequoia-Hcm, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy

New major risk - Revenue and earnings growth

Price target increased by 20% to US$74.39

CEO, President & Director notifies of intention to sell stock

Cytokinetics Presents Results from COURAGE-ALS At the 34th International Symposium on ALS/MND

Now 23% undervalued after recent price drop

CEO, President & Director exercised options and sold US$329k worth of stock

Insufficient new directors

CEO, President & Director notifies of intention to sell stock

Now 22% undervalued

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

CEO, President & Director exercised options and sold US$319k worth of stock

Cytokinetics, Incorporated to Report Q3, 2023 Results on Nov 02, 2023

Cytokinetics, Incorporated Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day

CEO, President & Director notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

Cytokinetics, Incorporated Presents Baseline Characteristics from SEQUOIA-HCM at the HCM Society

An Intrinsic Calculation For Cytokinetics, Incorporated (NASDAQ:CYTK) Suggests It's 37% Undervalued

CEO, President & Director notifies of intention to sell stock

Now 20% undervalued after recent price drop

CEO, President & Director notifies of intention to sell stock

CEO, President & Director exercised options and sold US$628k worth of stock

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

CEO, President & Director notifies of intention to sell stock

Cytokinetics, Incorporated to Report Q2, 2023 Results on Aug 03, 2023

CEO, President & Director notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

Cytokinetics, Incorporated Presents New Data in Patients with Non-Obstructive Hcm from Cohort 4 of Redwood-Hcm in Late-Breaking Clinical Trial Session At the European Society of Cardiology Heart Failure 2023 Congress

Insider notifies of intention to sell stock

Cytokinetics, Incorporated Announces Initiation of Phase 1 Clinical Study of CK-4021586

Consensus revenue estimates increase by 11%

Analysts Are Betting On Cytokinetics, Incorporated (NASDAQ:CYTK) With A Big Upgrade This Week

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CEO, President & Director exercised options and sold US$350k worth of stock

CEO, President & Director notifies of intention to sell stock

CEO, President & Director exercised options and sold US$318k worth of stock

CEO, President & Director notifies of intention to sell stock

Analysts Are Betting On Cytokinetics, Incorporated (NASDAQ:CYTK) With A Big Upgrade This Week

Full year 2022 earnings: EPS and revenues miss analyst expectations

VP & Chief Accounting Officer notifies of intention to sell stock

Cytokinetics, Incorporated to Report Q4, 2022 Results on Mar 01, 2023

Senior VP & CFO notifies of intention to sell stock

Cytokinetics, Incorporated's (NASDAQ:CYTK) Intrinsic Value Is Potentially 100% Above Its Share Price

Insider notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock